KRAS and lung cancer: Moreover, similar to the pharmacological inhibitors, when we used CRISPR/Cas9 to convert the genotype of the LLC mouse lung cancer cell line from KrasG12C to KrasWT and compared the phenotype between the isogenic cell pair LLC-KRASG12C and LLC-KRASWT, the latter showed much lower levels of KRAS activity and CD47 expression but much higher miR-34a and macrophage-mediated phagocytosis (Figure 8, G–I, and Supplemental Figure 14, D and E).